Article
Author: McKenna, Dillon ; Lazo, John S ; Subapanditha, Minomi ; Suk, Yujin ; McNicol, Jamie D ; Tatari, Nazanin ; Kieliszek, Agata M ; Venugopal, Chitra ; Moffat, Jason ; Salamoun, Joseph M ; Chafe, Shawn C ; Tong, Amy H Y ; Chen, David ; Singh, Sheila K ; Alizada, Zahra ; Wipf, Peter ; Rossotti, Martin A ; Liu, Lina ; Mobilio, Daniel ; Miletic, Petar ; Savage, Neil ; Chan, Katherine ; Anand, Alisha ; Shaikh, Muhammad Vaseem ; Brakel, Benjamin ; Ignatchenko, Vladimir ; Lu, Yu ; Kwiecien, Jacek M ; Puri, Anish ; Kislinger, Thomas ; Brown, Kevin R ; Henry, Kevin A ; Maich, William ; Tieu, David ; Aghaei, Nikoo ; Sharlow, Elizabeth R ; Grewal, Shan ; Chokshi, Chirayu R ; Mikolajewicz, Nicholas ; Lu, Jian-Qiang ; Kuhlmann, Laura ; Provias, John P ; Zhai, Kui
Resistance to genotoxic therapies and tumor recurrence are hallmarks of glioblastoma (GBM), an aggressive brain tumor. In this study, we investigated functional drivers of post-treatment recurrent GBM through integrative genomic analyses, genome-wide genetic perturbation screens in patient-derived GBM models and independent lines of validation. Specific genetic dependencies were found consistent across recurrent tumor models, accompanied by increased mutational burden and differential transcript and protein expression compared to its primary GBM predecessor. Our observations suggest a multi-layered genetic response to drive tumor recurrence and implicate PTP4A2 (protein tyrosine phosphatase 4A2) as a modulator of self-renewal, proliferation and tumorigenicity in recurrent GBM. Genetic perturbation or small-molecule inhibition of PTP4A2 acts through a dephosphorylation axis with roundabout guidance receptor 1 (ROBO1) and its downstream molecular players, exploiting a functional dependency on ROBO signaling. Because a pan-PTP4A inhibitor was limited by poor penetrance across the blood-brain barrier in vivo, we engineered a second-generation chimeric antigen receptor (CAR) T cell therapy against ROBO1, a cell surface receptor enriched across recurrent GBM specimens. A single dose of ROBO1-targeted CAR T cells doubled median survival in cell-line-derived xenograft (CDX) models of recurrent GBM. Moreover, in CDX models of adult lung-to-brain metastases and pediatric relapsed medulloblastoma, ROBO1 CAR T cells eradicated tumors in 50-100% of mice. Our study identifies a promising multi-targetable PTP4A-ROBO1 signaling axis that drives tumorigenicity in recurrent GBM, with potential in other malignant brain tumors.